Date: 2015-03-23
Type of information: Grant
Company: Immunovia (Sweden)
Investors: European Commission’s Horizon 2020 programme
Amount: € 4.2 million
Funding type: grant
Planned used: The EU grant application was approved to support the clinical validation of Immunovia’s biomarker signature, IMMray™ PanCan-d, the first blood-based test for early diagnosis of pancreatic cancer. As described in the Horizon 2020 evaluation report, the overall goal of this project is to provide clinical evidence that pancreatic cancer can be diagnosed in asymptomatic phases (stage I and II, respectively) when the patient can undergo surgery. The initial retrospective clinical studies with almost 1 000 patients/controls have already confirmed that the new biomarker signature, IMMray™ PanCan-d, can accurately separate pancreatic cancer patients from healthy individuals with a blood test.
Others: * On March, 23, 2015, Immunovia announced that the company received the approval for a two-year € 4.2 million funding from Horizon 2020.
Therapeutic area: Cancer - Oncology - Diagnostic
